
|Videos|April 19, 2022
The Role of Biomarker Testing in Patients with Myelofibrosis
Author(s)Naveen Pemmaraju, MD
Dr Naveen Pemmaraju explains the relationship of the JAK/STAT pathway to myelofibrosis and the molecular mutations he looks for with biomarker testing.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5

























